Methylphenidate Treatment of Cognitive Dysfunction in Adults After Mild to Moderate Traumatic Brain Injury: Rationale, Efficacy, and Neural Mechanisms
Positive effects of methylphenidate (MPH) on attention and cognitive processing speed have been reported in studies of patients with moderate to severe traumatic brain injury (TBI). Studies which have acquired functional brain imaging before and while using MPH have also found alteration of brain ac...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2019-09-01
|
Series: | Frontiers in Neurology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fneur.2019.00925/full |
id |
doaj-131e0d0e193b49078fb205943b38dbd7 |
---|---|
record_format |
Article |
spelling |
doaj-131e0d0e193b49078fb205943b38dbd72020-11-25T01:18:42ZengFrontiers Media S.A.Frontiers in Neurology1664-22952019-09-011010.3389/fneur.2019.00925455397Methylphenidate Treatment of Cognitive Dysfunction in Adults After Mild to Moderate Traumatic Brain Injury: Rationale, Efficacy, and Neural MechanismsHarvey Levin0Harvey Levin1Maya Troyanskaya2Maya Troyanskaya3JoAnn Petrie4Elisabeth A. Wilde5Elisabeth A. Wilde6Elisabeth A. Wilde7Jill V. Hunter8Tracy J. Abildskov9Randall S. Scheibel10Randall S. Scheibel11Department of Physical Medicine & Rehabilitation, Baylor College of Medicine, Houston, TX, United StatesMichael E. DeBakey Veterans Affairs Medical Center, Houston, TX, United StatesDepartment of Physical Medicine & Rehabilitation, Baylor College of Medicine, Houston, TX, United StatesMichael E. DeBakey Veterans Affairs Medical Center, Houston, TX, United StatesDepartment of Neurology, University of Utah, Salt Lake City, UT, United StatesDepartment of Physical Medicine & Rehabilitation, Baylor College of Medicine, Houston, TX, United StatesDepartment of Neurology, University of Utah, Salt Lake City, UT, United StatesGeorge E. Wahlen VA Salt Lake City Healthcare System, Salt Lake City, UT, United StatesBaylor College of Medicine, Texas Children's Hospital, Houston, TX, United StatesDepartment of Neurology, University of Utah, Salt Lake City, UT, United StatesDepartment of Physical Medicine & Rehabilitation, Baylor College of Medicine, Houston, TX, United StatesMichael E. DeBakey Veterans Affairs Medical Center, Houston, TX, United StatesPositive effects of methylphenidate (MPH) on attention and cognitive processing speed have been reported in studies of patients with moderate to severe traumatic brain injury (TBI). Studies which have acquired functional brain imaging before and while using MPH have also found alteration of brain activation while performing a cognitive task; in some studies, this alteration of activation in selective brain regions was also related to improved performance on cognitive tests administered outside of the scanning environment. Enhanced cognitive performance has been reported after single doses of MPH and after daily treatment over durations of up to and exceeding 1 month. Preclinical research and both positron emission tomography and single photon emission tomography of humans have shown that MPH increases extracellular dopamine and norepinephrine; the dose effects of MPH have an inverted U-shaped function where high doses may cause insomnia, nervousness, and increased heart rate among other symptoms and impair cognitive performance, whereas too low a dose fails to improve cognitive performance. In the past 5 years, small clinical trials, and experimental pilot studies have found therapeutic effects of single and repeated low doses of MPH in patients with mild TBI who reported cognitive dysfunction. This literature also suggests that MPH may interact with concurrent cognitive interventions to enhance their effects. This focused review will critically evaluate the recent literature on MPH effects on cognitive dysfunction after mild to moderate TBI. To elucidate the neural mechanisms of MPH effects, this review will also include recent imaging research, preclinical, and experimental human studies.https://www.frontiersin.org/article/10.3389/fneur.2019.00925/fulltraumatic brain injurymethylphenidateclinical trialsimagingdopaminecognition |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Harvey Levin Harvey Levin Maya Troyanskaya Maya Troyanskaya JoAnn Petrie Elisabeth A. Wilde Elisabeth A. Wilde Elisabeth A. Wilde Jill V. Hunter Tracy J. Abildskov Randall S. Scheibel Randall S. Scheibel |
spellingShingle |
Harvey Levin Harvey Levin Maya Troyanskaya Maya Troyanskaya JoAnn Petrie Elisabeth A. Wilde Elisabeth A. Wilde Elisabeth A. Wilde Jill V. Hunter Tracy J. Abildskov Randall S. Scheibel Randall S. Scheibel Methylphenidate Treatment of Cognitive Dysfunction in Adults After Mild to Moderate Traumatic Brain Injury: Rationale, Efficacy, and Neural Mechanisms Frontiers in Neurology traumatic brain injury methylphenidate clinical trials imaging dopamine cognition |
author_facet |
Harvey Levin Harvey Levin Maya Troyanskaya Maya Troyanskaya JoAnn Petrie Elisabeth A. Wilde Elisabeth A. Wilde Elisabeth A. Wilde Jill V. Hunter Tracy J. Abildskov Randall S. Scheibel Randall S. Scheibel |
author_sort |
Harvey Levin |
title |
Methylphenidate Treatment of Cognitive Dysfunction in Adults After Mild to Moderate Traumatic Brain Injury: Rationale, Efficacy, and Neural Mechanisms |
title_short |
Methylphenidate Treatment of Cognitive Dysfunction in Adults After Mild to Moderate Traumatic Brain Injury: Rationale, Efficacy, and Neural Mechanisms |
title_full |
Methylphenidate Treatment of Cognitive Dysfunction in Adults After Mild to Moderate Traumatic Brain Injury: Rationale, Efficacy, and Neural Mechanisms |
title_fullStr |
Methylphenidate Treatment of Cognitive Dysfunction in Adults After Mild to Moderate Traumatic Brain Injury: Rationale, Efficacy, and Neural Mechanisms |
title_full_unstemmed |
Methylphenidate Treatment of Cognitive Dysfunction in Adults After Mild to Moderate Traumatic Brain Injury: Rationale, Efficacy, and Neural Mechanisms |
title_sort |
methylphenidate treatment of cognitive dysfunction in adults after mild to moderate traumatic brain injury: rationale, efficacy, and neural mechanisms |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Neurology |
issn |
1664-2295 |
publishDate |
2019-09-01 |
description |
Positive effects of methylphenidate (MPH) on attention and cognitive processing speed have been reported in studies of patients with moderate to severe traumatic brain injury (TBI). Studies which have acquired functional brain imaging before and while using MPH have also found alteration of brain activation while performing a cognitive task; in some studies, this alteration of activation in selective brain regions was also related to improved performance on cognitive tests administered outside of the scanning environment. Enhanced cognitive performance has been reported after single doses of MPH and after daily treatment over durations of up to and exceeding 1 month. Preclinical research and both positron emission tomography and single photon emission tomography of humans have shown that MPH increases extracellular dopamine and norepinephrine; the dose effects of MPH have an inverted U-shaped function where high doses may cause insomnia, nervousness, and increased heart rate among other symptoms and impair cognitive performance, whereas too low a dose fails to improve cognitive performance. In the past 5 years, small clinical trials, and experimental pilot studies have found therapeutic effects of single and repeated low doses of MPH in patients with mild TBI who reported cognitive dysfunction. This literature also suggests that MPH may interact with concurrent cognitive interventions to enhance their effects. This focused review will critically evaluate the recent literature on MPH effects on cognitive dysfunction after mild to moderate TBI. To elucidate the neural mechanisms of MPH effects, this review will also include recent imaging research, preclinical, and experimental human studies. |
topic |
traumatic brain injury methylphenidate clinical trials imaging dopamine cognition |
url |
https://www.frontiersin.org/article/10.3389/fneur.2019.00925/full |
work_keys_str_mv |
AT harveylevin methylphenidatetreatmentofcognitivedysfunctioninadultsaftermildtomoderatetraumaticbraininjuryrationaleefficacyandneuralmechanisms AT harveylevin methylphenidatetreatmentofcognitivedysfunctioninadultsaftermildtomoderatetraumaticbraininjuryrationaleefficacyandneuralmechanisms AT mayatroyanskaya methylphenidatetreatmentofcognitivedysfunctioninadultsaftermildtomoderatetraumaticbraininjuryrationaleefficacyandneuralmechanisms AT mayatroyanskaya methylphenidatetreatmentofcognitivedysfunctioninadultsaftermildtomoderatetraumaticbraininjuryrationaleefficacyandneuralmechanisms AT joannpetrie methylphenidatetreatmentofcognitivedysfunctioninadultsaftermildtomoderatetraumaticbraininjuryrationaleefficacyandneuralmechanisms AT elisabethawilde methylphenidatetreatmentofcognitivedysfunctioninadultsaftermildtomoderatetraumaticbraininjuryrationaleefficacyandneuralmechanisms AT elisabethawilde methylphenidatetreatmentofcognitivedysfunctioninadultsaftermildtomoderatetraumaticbraininjuryrationaleefficacyandneuralmechanisms AT elisabethawilde methylphenidatetreatmentofcognitivedysfunctioninadultsaftermildtomoderatetraumaticbraininjuryrationaleefficacyandneuralmechanisms AT jillvhunter methylphenidatetreatmentofcognitivedysfunctioninadultsaftermildtomoderatetraumaticbraininjuryrationaleefficacyandneuralmechanisms AT tracyjabildskov methylphenidatetreatmentofcognitivedysfunctioninadultsaftermildtomoderatetraumaticbraininjuryrationaleefficacyandneuralmechanisms AT randallsscheibel methylphenidatetreatmentofcognitivedysfunctioninadultsaftermildtomoderatetraumaticbraininjuryrationaleefficacyandneuralmechanisms AT randallsscheibel methylphenidatetreatmentofcognitivedysfunctioninadultsaftermildtomoderatetraumaticbraininjuryrationaleefficacyandneuralmechanisms |
_version_ |
1725140972072861696 |